TGTX Q1 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M+713.5% YoY

Gross Profit

$58M91.3% margin

Operating Income

-$9M-14.6% margin

Net Income

-$11M-16.9% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+44.4%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$373M

Total Liabilities

$213M

Stockholders' Equity

$160M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$8M	+713.5%
Gross Profit	$58M	$7M	+734.3%
Operating Income	-$9M	-$37M	+74.9%
Net Income	-$11M	-$39M	+72.7%

Revenue Segments

Product

$50M80%

Milestone

$13M20%

Other Revenue

$415,0001%

License Revenue

$38,0000%

Royalty

$33,0000%